BIIB vs GILD
Figures are each company’s own, from its most recent annual filing; fiscal year ends differ. Both are classified by the SEC under Biological Products, (No Diagnostic Substances).
| Metric | BIIBBIOGEN INC. | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Revenue | $9.89B | $29.44B |
| Gross margin | 75.7% | 78.8% |
| Operating income | Unavailable | $10.02B |
| Operating margin | Unavailable | 34.0% |
| Net income | $1.29B | $8.51B |
| Net margin | 13.1% | 28.9% |
| Free cash flow | $2.05B | $9.46B |
| Total assets | $29.44B | $59.02B |
| Total equity | $18.26B | $22.62B |
| Diluted EPS | $8.79 | $6.78 |
Every figure links to the filing it came from on each company page: BIIB and GILD. See the methodology for how each one is chosen.